WWH (Washington DC)


In December 2013, the Division of AIDS of the National Institute of Allergy and Infectious Diseases selected Whitman-Walker Health as the only new domestic Clinical Research Site in the most recent competition for funding. WWH is thrilled to join the AIDS Clinical Trials Group and to provide its patients access to the cutting-edge, scientific work in the ACTG. In its first two years as an ACTG site, WWH is proud to have enrolled over 25 participants into 5 distinct ACTG trials and continues to thrive and grow as a site. WWH has a long history of participating in advanced clinical research, starting in 1987 when some of the first trials on AZT for HIV treatment were conducted here. Since then, the health center’s investigators and staff have conducted over 70 studies that have included over 2,000 patients. WWH’s research studies look at new ways to prevent or treat diseases in the community, like HIV and hepatitis. WWH’s portfolio includes clinical trials that test how well new medications work and how safe the medications are for patients; as well as behavioral studies that look at such topics as disease prevention and medical adherence.
 
WWH has worked closely with the National Institutes of Health and the Johns Hopkins University Bloomberg School of Public Health on the Multicenter AIDS Cohort Study and multiple HIV/STI prevention projects. The health center has also collaborated with industry sponsors to evaluate all of the current therapies used to treated HIV and viral hepatitis. The effectiveness and tolerability of these medications have changed dramatically over the past 20 years. WWH and its patients have been at the forefront of contributing to research that has led to all of the currently approved single tablet regimens for HIV and the direct acting agents for hepatitis C treatment. Becoming a part of the ACTG will offer WWH the opportunity to conduct additional areas of research, including cure research and studies on more novel immunotherapies for HIV.
 
The WWH CRS operates from Whitman-Walker Health’s two sites on 14th Street between the U Street Corridor, Dupont Circle and Logan Circle in Northwest Washington, DC. Most patient visits are conducted at WWH’s site at 1525 14th Street NW, a state of the art facility that opened in May 2015. WWH’s laboratory and pharmacy are located there, as well as WWH’s main medical, dental and behavioral health services. WWH’s second site, the Elizabeth Taylor Medical Center at 1701 14th Street NW, houses investigator and staff offices, plus WWH’s regulatory and data management teams.
 
Translating research into clinical practice and bridging community efforts and scientific initiatives to combat HIV are at the center of WWH’s mission and values. The health center is thrilled to collaborate with JHU and BJMC as part of the ACTG and looks forward to making significant advancements in HIV and hepatitis research.
 

Clinical Trials

A5321: Decay of HIV-1 Reservoirs in Patients on Long-Term...

The study is being done to try to determine which factors contribute to the persistence of HIV (how long the virus remains) in...

Read More

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

A5320: Viral Hepatitis C Infection Long-term Cohort Study...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More